Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)

Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the Company’s OligoPhore™ platform and siRNA targeting the p65 protein, a component of the NF-κB transcription factor.

Related tickers: CYTO.

Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA -- April 24, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of the detailed results from the NASAR clinical trial with Bentrio® nasal spray in seasonal allergic rhinitis (SAR). The peer-reviewed article appeared in Allergy,1 which is published by the European Academy of Allergy and Clinical Immunology and recognizes as one of the highest-ranking journals in the field of allergology. Bentrio (AM-301) is a drug-free and preservative-free nasal spray designed to help protect against airborne allergens such as pollen or house dust mites.

Related tickers: CYTO.